- The product developed by Pfizer and BioNTech is 90% effective, the producer says. The Phase 3 clinical trial of BNT162b2 began on July 27 and has enrolled 43,538 participants to date, 38,955 of whom have received a second dose of the vaccine candidate as of November 8, 2020.
- Approximately 42% of global participants and 30% of U.S. participants have racially and ethnically diverse backgrounds. The trial is continuing to enroll and is expected to continue through the final analysis when a total of 164 confirmed COVID-19 cases have accrued.
- After discussion with the FDA, the companies recently elected to drop the 32-case interim analysis and conduct the first interim analysis at a minimum of 62 cases. Upon the conclusion of those discussions, the evaluable case count reached 94 and the Data Monitoring Committee performed its first analysis on all cases. The case split between vaccinated individuals and those who received the placebo indicates a vaccine efficacy rate above 90%, at seven days after the second dose.
- Pfizer says there are no serious side effects. If key indicators are safe, the world may have a tool to tackle the pandemic in a week.
- The European Commission has already agreed to sign an agreement with the developers on the purchase of 300 million doses of the coronavirus vaccine.
Zelensky asks Merkel to assist in allocating COVID-19 vaccine to Ukraine

The parties agreed to further coordinate efforts to overcome the consequences of the pandemic.
President of Ukraine Volodymyr Zelensky on November 10 had a phone call with Germany's Chancellor Angela Merkel during which he asked the German leader to assist in supplying a U.S.-German-developed COVID-19 vaccine to Ukraine.
"We welcome the breakthrough achieved by the German company BioNTech together with the American company Pfizer in the development of a coronavirus vaccine. This is very encouraging news. I would like to ask for your assistance in taking into account the interests of Ukraine when planning the supply of COVID-19 vaccine," Zelensky said, according to the press service of the Ukrainian President's Office.
Pfizer vaccine
Latest news
Latest newsThe United States Rapidly Expands Missile Production: Pentagon Accelerates Output of Tomahawks and Other Critical Weapons
24.Aug.2026
Record Supplies: Armenia Boosts Fish Exports to Georgia
23.Aug.2026
Political Battle During Wartime: Zelensky Opposes Elections
23.Aug.2026
Romania Approves Construction of One of the Largest Solar Power Plants in Europe
23.Aug.2026
Ex-Ukrainian Defence Minister Fails in Bid to Pressure Zelenskiy
22.Aug.2026
Upper Lars: Why Border Queues Have Become a Political Signal for Georgia and Russia
22.Aug.2026
Russia-Ukraine War: No Decisive Breakthrough on the Front and Intensifying Ukrainian Deep Strikes on Russia
21.Aug.2026
TRIPP, Peace, and a New Geopolitical Crossroads: How Armenia Has Changed One Year After Washington
20.Aug.2026
Tokayev Updates Kazakhstan Foreign Policy Concept: Astana Strengthens Its Strategic Multi Vector Approach
19.Aug.2026
Ukraine Turns Ground Robots into a New Tool in the Fight Against Russia
19.Aug.2026
Tehran Threatens a New Round of War After Talks With the US Collapse
18.Aug.2026
Drones Over Moldova: Accident or a New Threat to National Security?
17.Aug.2026
Spanish F-18 Fighter Jet Shoots Down Drone That Violated Romanian Airspace
17.Aug.2026
The Black Sea Becomes a Risk Zone: Can Turkiye Protect Key Trade Routes?
16.Aug.2026
Ukraine Intensifies Long-Range Strikes: Flamingo Missiles Hit a Rocket and Space Center and Airbase in Russia
15.Aug.2026

24 Aug 2026


